Daoyuan Si1, Beibei Du2, Lujia Ni2, Bo Yang2, Huan Sun2, Nan Jiang2, Guohui Liu2, Stéphane Massé2, Lina Jin2, Jared Nanthakumar2, Abhishek Bhaskaran2, Ping Yang2, Kumaraswamy Nanthakumar1. 1. Department of Cardiology (Si, Du, Sun, Liu, Yang), The Third Hospital of Jilin University, Jilin Provincial Molecular Biology Research Center for Precision Medicine of Major Cardiovascular Disease, Changchun, China; Department of Ultrasound (Ni), The Third Hospital of Jilin University, Changchun, China; Institute of Organ Transplantation (Yang), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Intensive Care Unit (Jiang), The Third Hospital of Jilin University, Changchun, China; The Hull Family Laboratory (Massé, J. Nanthakumar, Bhaskaran, K. Nanthakumar), Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto, Toronto, Ont.; Department of Epidemiology and Biostatistics (Jin), School of Public Health, Jilin University, Changchun, Jilin, China sidaoyuan@jlu.edu.cn kumar.nanthakumar@uhn.ca. 2. Department of Cardiology (Si, Du, Sun, Liu, Yang), The Third Hospital of Jilin University, Jilin Provincial Molecular Biology Research Center for Precision Medicine of Major Cardiovascular Disease, Changchun, China; Department of Ultrasound (Ni), The Third Hospital of Jilin University, Changchun, China; Institute of Organ Transplantation (Yang), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Intensive Care Unit (Jiang), The Third Hospital of Jilin University, Changchun, China; The Hull Family Laboratory (Massé, J. Nanthakumar, Bhaskaran, K. Nanthakumar), Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto, Toronto, Ont.; Department of Epidemiology and Biostatistics (Jin), School of Public Health, Jilin University, Changchun, Jilin, China.
Abstract
BACKGROUND: Cardiac injury is common in severe coronavirus disease 2019 (COVID-19) and is associated with poor outcomes. We aimed to study predictors of in-hospital death, characteristics of arrhythmias and the effects of QT-prolonging therapy in patients with cardiac injury. METHODS: We conducted a retrospective cohort study involving patients with severe COVID-19 who were admitted to Tongji Hospital in Wuhan, China, between Jan. 29 and Mar. 8, 2020. Among patients who had cardiac injury, which we defined as an elevated level of cardiac troponin I (cTnI), we identified demographic and clinical characteristics associated with mortality and need for invasive ventilation. RESULTS: Among 1284 patients with severe COVID-19, 1159 had a cTnI level measured on admission to hospital, of whom 170 (14.7%) had results that showed cardiac injury. We found that mortality was markedly higher in patients with cardiac injury (71.2% v. 6.6%, p < 0.001). We determined that initial cTnI (per 10-fold increase, hazard ratio [HR] 1.32, 95% confidence interval [CI] 1.06-1.66) and peak cTnI level during illness (per 10-fold increase, HR 1.70, 95% CI 1.38-2.10) were associated with poor survival. Peak cTnI was also associated with the need for invasive ventilation (odds ratio 3.02, 95% CI 1.92-4.98). We found arrhythmias in 44 of the 170 patients with cardiac injury (25.9%), including 6 patients with ventricular tachycardia or fibrillation, all of whom died. We determined that patients who received QT-prolonging drugs had longer QTc intervals than those who did not receive them (difference in medians, 45 ms, p = 0.01), but such treatment was not independently associated with mortality (HR 1.04, 95% CI 0.69-1.57). INTERPRETATION: We found that in patients with COVID-19 and cardiac injury, initial and peak cTnI levels were associated with poor survival, and peak cTnI was a predictor of need for invasive ventilation. Patients with COVID-19 warrant assessment for cardiac injury and monitoring, especially if therapy that can prolong repolarization is started. TRIAL REGISTRATION: Chinese Clinical Trial Registry, No. ChiCTR2000031301.
BACKGROUND:Cardiac injury is common in severe coronavirus disease 2019 (COVID-19) and is associated with poor outcomes. We aimed to study predictors of in-hospital death, characteristics of arrhythmias and the effects of QT-prolonging therapy in patients with cardiac injury. METHODS: We conducted a retrospective cohort study involving patients with severe COVID-19 who were admitted to Tongji Hospital in Wuhan, China, between Jan. 29 and Mar. 8, 2020. Among patients who had cardiac injury, which we defined as an elevated level of cardiac troponin I (cTnI), we identified demographic and clinical characteristics associated with mortality and need for invasive ventilation. RESULTS: Among 1284 patients with severe COVID-19, 1159 had a cTnI level measured on admission to hospital, of whom 170 (14.7%) had results that showed cardiac injury. We found that mortality was markedly higher in patients with cardiac injury (71.2% v. 6.6%, p < 0.001). We determined that initial cTnI (per 10-fold increase, hazard ratio [HR] 1.32, 95% confidence interval [CI] 1.06-1.66) and peak cTnI level during illness (per 10-fold increase, HR 1.70, 95% CI 1.38-2.10) were associated with poor survival. Peak cTnI was also associated with the need for invasive ventilation (odds ratio 3.02, 95% CI 1.92-4.98). We found arrhythmias in 44 of the 170 patients with cardiac injury (25.9%), including 6 patients with ventricular tachycardia or fibrillation, all of whom died. We determined that patients who received QT-prolonging drugs had longer QTc intervals than those who did not receive them (difference in medians, 45 ms, p = 0.01), but such treatment was not independently associated with mortality (HR 1.04, 95% CI 0.69-1.57). INTERPRETATION: We found that in patients with COVID-19 and cardiac injury, initial and peak cTnI levels were associated with poor survival, and peak cTnI was a predictor of need for invasive ventilation. Patients with COVID-19 warrant assessment for cardiac injury and monitoring, especially if therapy that can prolong repolarization is started. TRIAL REGISTRATION: Chinese Clinical Trial Registry, No. ChiCTR2000031301.
Authors: Vijay S Chauhan; Eugene Downar; Kumaraswamy Nanthakumar; John D Parker; Heather J Ross; Wilson Chan; Peter Picton Journal: Am J Physiol Heart Circ Physiol Date: 2005-08-19 Impact factor: 4.733
Authors: Matt Arentz; Eric Yim; Lindy Klaff; Sharukh Lokhandwala; Francis X Riedo; Maria Chong; Melissa Lee Journal: JAMA Date: 2020-04-28 Impact factor: 56.272
Authors: C-M Yu; R S-M Wong; E B Wu; S-L Kong; J Wong; G W-K Yip; Y O Y Soo; M L S Chiu; Y-S Chan; D Hui; N Lee; A Wu; C-B Leung; J J-Y Sung Journal: Postgrad Med J Date: 2006-02 Impact factor: 2.401
Authors: Abdullah Assiri; Allison McGeer; Trish M Perl; Connie S Price; Abdullah A Al Rabeeah; Derek A T Cummings; Zaki N Alabdullatif; Maher Assad; Abdulmohsen Almulhim; Hatem Makhdoom; Hossam Madani; Rafat Alhakeem; Jaffar A Al-Tawfiq; Matthew Cotten; Simon J Watson; Paul Kellam; Alimuddin I Zumla; Ziad A Memish Journal: N Engl J Med Date: 2013-06-19 Impact factor: 91.245
Authors: Mustafa Saad; Ali S Omrani; Kamran Baig; Abdelkarim Bahloul; Fatehi Elzein; Mohammad Abdul Matin; Mohei A A Selim; Mohammed Al Mutairi; Daifullah Al Nakhli; Amal Y Al Aidaroos; Nisreen Al Sherbeeni; Hesham I Al-Khashan; Ziad A Memish; Ali M Albarrak Journal: Int J Infect Dis Date: 2014-10-07 Impact factor: 3.623
Authors: Elissa Driggin; Mahesh V Madhavan; Behnood Bikdeli; Taylor Chuich; Justin Laracy; Giuseppe Biondi-Zoccai; Tyler S Brown; Caroline Der Nigoghossian; David A Zidar; Jennifer Haythe; Daniel Brodie; Joshua A Beckman; Ajay J Kirtane; Gregg W Stone; Harlan M Krumholz; Sahil A Parikh Journal: J Am Coll Cardiol Date: 2020-03-19 Impact factor: 24.094
Authors: Jorge Sanz-Sánchez; Dimitrios A Vrachatis; Bernhard Reimers; Spyridon G Deftereos; Marinos Kallikourdis; Marco Vicenzi; George Giannopoulos; Sotiria G Giotaki; Dimitrios Tousoulis; Giuseppe Ferrante; Gianluigi Condorelli; Giulio G Stefanini Journal: Hellenic J Cardiol Date: 2020-08-08